Drug repurposing: progress, challenges and recommendations

Sudeep Pushpakom(University of Liverpool), Munir Pirmohamed(University of Liverpool), Patrick A. Eyers(University of Liverpool), Philippe Sanséau(GlaxoSmithKline (United Kingdom)), Joanna Latimer(University of York), Tim Guilliams, Andrew D. Wells(Children's Hospital of Philadelphia), Shirley Hopper, David Cavalla(Numedicus (United Kingdom)), Francesco Iorio(Human Technopole), Alan Norris(University of Liverpool), Andrew J. Doig(University of Manchester), Katherine J. Escott(AstraZeneca (United Kingdom)), Christine J. McNamee(University of Liverpool)
Nature Reviews Drug Discovery
October 12, 2018
10.1038/nrd.2018.168
Cited by 4,649

Related Papers

Systematic identification of genomic markers of drug sensitivity in cancer cells
|Nature|2012|2.6k
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
|Cell|2015|2.4k
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
|Nature|2019|1.4k
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
|Nature Communications|2014|906